Latest Insider Transactions at Blueprint Medicines Corp (BPMC)
This section provides a real-time view of insider transactions for Blueprint Medicines Corp (BPMC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Blueprint Medicines Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Blueprint Medicines Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 17
2025
|
Habib J Dable Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,742
-100.0%
|
-
|
|
Jul 17
2025
|
Habib J Dable Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,902
-30.86%
|
-
|
|
Jul 17
2025
|
Michael Landsittel Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
43,175
-100.0%
|
-
|
|
Jul 17
2025
|
Michael Landsittel Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
51,102
-54.2%
|
-
|
|
Jul 17
2025
|
Michael Landsittel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,353
+18.47%
|
-
|
|
Jul 17
2025
|
Debra Durso Bumpus Chief People Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
19,856
-100.0%
|
-
|
|
Jul 17
2025
|
Debra Durso Bumpus Chief People Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
51,103
-72.02%
|
-
|
|
Jul 17
2025
|
Debra Durso Bumpus Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,353
+23.13%
|
-
|
|
Jul 17
2025
|
Tracey L Mc Cain EVP & Chief Legal Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
37,092
-100.0%
|
-
|
|
Jul 17
2025
|
Tracey L Mc Cain EVP & Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
51,103
-57.94%
|
-
|
|
Jul 17
2025
|
Tracey L Mc Cain EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,353
+19.49%
|
-
|
|
Jul 17
2025
|
Daniella Beckman Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,842
-100.0%
|
-
|
|
Jul 17
2025
|
Daniella Beckman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,902
-26.47%
|
-
|
|
Jul 17
2025
|
Fouad Namouni PRESIDENT, R & D |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
31,956
-100.0%
|
-
|
|
Jul 17
2025
|
Fouad Namouni PRESIDENT, R & D |
SELL
Sale (or disposition) back to the issuer
|
Direct |
83,281
-72.27%
|
-
|
|
Jul 17
2025
|
Fouad Namouni PRESIDENT, R & D |
BUY
Grant, award, or other acquisition
|
Direct |
39,456
+25.51%
|
-
|
|
Jul 17
2025
|
Mark Alan Goldberg Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
18,254
-100.0%
|
-
|
|
Jul 17
2025
|
Mark Alan Goldberg Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,902
-17.61%
|
-
|
|
Jul 17
2025
|
Alexis Borisy Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
74,160
-100.0%
|
-
|
|
Jul 17
2025
|
Alexis Borisy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,902
-5.0%
|
-
|
|
Jul 17
2025
|
Kate Haviland Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
70,729
-100.0%
|
-
|
|
Jul 17
2025
|
Kate Haviland Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
224,410
-76.04%
|
-
|
|
Jul 17
2025
|
Kate Haviland Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
129,210
+30.45%
|
-
|
|
Jul 17
2025
|
Christina Rossi Chief Operating Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
20,628
-100.0%
|
-
|
|
Jul 17
2025
|
Christina Rossi Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
82,374
-79.97%
|
-
|
|
Jul 17
2025
|
Christina Rossi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,456
+27.7%
|
-
|
|
Jul 17
2025
|
Percy H. Carter Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,894
-100.0%
|
-
|
|
Jul 17
2025
|
Percy H. Carter Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
56,614
-75.98%
|
-
|
|
Jul 17
2025
|
Percy H. Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,353
+22.28%
|
-
|
|
Jul 17
2025
|
Lynn Seely Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
13,254
-100.0%
|
-
|
|
Jul 17
2025
|
Lynn Seely Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,902
-22.74%
|
-
|
|
Jul 17
2025
|
L. Becker Hewes Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,607
-100.0%
|
-
|
|
Jul 17
2025
|
L. Becker Hewes Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
50,165
-96.9%
|
-
|
|
Jul 17
2025
|
L. Becker Hewes Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,353
+29.2%
|
-
|
|
Jul 17
2025
|
Lonnel Coats Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,144
-100.0%
|
-
|
|
Jul 17
2025
|
John Tsai Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,742
-100.0%
|
-
|
|
Jul 17
2025
|
John Tsai Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,902
-30.86%
|
-
|
|
Jul 17
2025
|
Ariel Hurley Principal Accounting Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,378
-100.0%
|
-
|
|
Jul 17
2025
|
Ariel Hurley Principal Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,146
-82.7%
|
-
|
|
Jul 17
2025
|
Ariel Hurley Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,460
+11.19%
|
-
|
|
Jul 17
2025
|
Jeffrey W. Albers Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
144,755
-100.0%
|
-
|
|
Jul 17
2025
|
Jeffrey W. Albers Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,777
-3.84%
|
-
|
|
Jul 17
2025
|
Philina Lee Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
13,184
-100.0%
|
-
|
|
Jul 17
2025
|
Philina Lee Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
50,165
-79.19%
|
-
|
|
Jul 17
2025
|
Philina Lee Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,353
+25.21%
|
-
|
|
Jul 03
2025
|
Percy H. Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,051
-1.94%
|
$134,528
$128.25 P/Share
|
|
Jul 03
2025
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,172
-1.81%
|
$150,016
$128.25 P/Share
|
|
Jun 18
2025
|
Lynn Seely Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,902
+18.53%
|
$499,456
$128.12 P/Share
|
|
Jun 18
2025
|
Mark Alan Goldberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,902
+14.97%
|
$499,456
$128.12 P/Share
|
|
Jun 18
2025
|
Jeffrey W. Albers Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,902
+2.53%
|
$499,456
$128.12 P/Share
|